(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...
Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse.
(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...
Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3. Sanofi released its third-quarter earnings report on Friday, beating ...
(Bloomberg) -- After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into ...
Sanofi and Sudair Pharma Company (SPC) have joined forces to establish a state-of-the-art manufacturing facility within the Kingdom of Saudi Arabia, dedicated to the full production including delivery ...
Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing iconic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback